Pharmacology and neuroprotective properties of rasagiline.
Rasagiline [R(+)-N-propargyl-1-aminoindane] is a selective irreversible inhibitor of MAO-B which is not metabolised to amphetamine-like derivatives. Like deprenyl, when given to rats in a dose selective for inhibition of MAO-B, it does not affect striatal extracellular fluid dopamine levels, but when administered chronically (21 days) it increased striatal microdialysate dopamine without reduction in deaminated metabolites. Similarly to deprenyl, rasagiline (10(-6)M) increased the percentage of tyrosine hydroxylase positive cells in a primary culture of rat fetal mesencephalic cells (6 days in culture). Rasagiline, but not deprenyl, also increased the number of neurons per field in this organotypic culture.
Finberg
J P
JP
Pharmacology Unit, Rappaport Faculty of Medicine, Technion, Haifa, Israel.
Lamensdorf
I
I
Commissiong
J W
JW
Youdim
M B
MB
D000818:Animals; D002478:Cells, Cultured; D003342:Corpus Striatum / Q000187:drug effects* / Q000378:metabolism; D004298:Dopamine / Q000096:biosynthesis; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007189:Indans / Q000494:pharmacology / Q000627:therapeutic use*; D007980:Levodopa / Q000494:pharmacology; D008636:Mesencephalon / Q000166:cytology / Q000187:drug effects* / Q000196:embryology; D017551:Microdialysis; D008928:Mitochondria / Q000187:drug effects / Q000201:enzymology; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D009419:Nerve Tissue Proteins / Q000032:analysis; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D014446:Tyrosine 3-Monooxygenase / Q000032:analysis
D007189:Indans; D008996:Monoamine Oxidase Inhibitors; D009419:Nerve Tissue Proteins; D018696:Neuroprotective Agents; C031967:rasagiline; D007980:Levodopa; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine